Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Chemomab Therapeutics
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 21, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
August 12, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
July 26, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
March 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Tickers
CMMB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.